Medistim — Interim / Quarterly Report 2010

Apr 30, 2010

1 quarter results 2010 for MediStim ASA

The newly launched ultrasound imaging instrument

VeriQC is now in clinical use in 5 countries. VeriQC

received during the quarter approval for sale in

Japan. Sales for the quarter were affected by a

stronger NOK and an extended sales cycle. There was

no activation of development expenses in first

quarter 2010. The general assembly held the 29th of

April decided a dividend of NOK 0.90 per share where

NOK 0.15 is extraordinary dividend related to

MediStims 25 year anniversary. The same general

assembly decided to amortize 523.989 of own shares.